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Introduction
Omnia, quae nunc vetustissima creduntur, nova
fuere [All, which we consider now as most ancient,
was new once]
Tacitus, Annals, Book XI, 24
As with everything else in science, biological research
involves the continuous updating of physiological phenom-
ena, sometimes subverting the certainty ‘written in stone’.
That is also true of prostate-specific antigen (PSA), an
antigen discovered in the 1970s and introduced to urologi-
cal practice about 15 years ago [1]. Although it is widely
used as the most sensitive marker available so far for
screening, diagnosis and monitoring human prostate
cancer progression as well as response to therapy, discov-
eries over the past decade have unequivocally indicated
that the original antigen PSA is no longer prostate-specific,
shedding light on the multifunctional behaviour of this
‘novel’ serine protease [2]. The main characteristics of this
kallikrein, which belongs to the family of serine proteases,
have previously been described in detail [3] and are there-
fore mentioned only briefly here. The glandular kallikrein
gene family is composed of three genes, localized on
chromosome 19q13.3–q13.4; the KLK-3 gene locus
encodes the extracellular serine protease PSA, which has
also been named human glandular kallikrein 3 (hK3). In the
prostate, PSA expression is localized to the differentiated,
secretory columnar cells of the glandular epithelium. Bio-
chemically, it is a 33 kDa single-chain glycoprotein with
chymotrypsin-like activity that requires post-translational
processing for its full proteolytic activity.
Physiologically, PSA has a role in the dissolution of the gel
structure of freshly ejaculated semen, through specific
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Since its identification, much information has been obtained about prostate-specific antigen (PSA, or
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proteolysis of both high molecular mass semenogelin and
fibronectin. In seminal fluid about two thirds of PSA is
enzymically active, whereas the remainder is inactive and
does not bind to protease inhibitors. Low levels of PSA
are normally released into the blood and its predominant
molecular form is that complexed with a1-antichymo-
trypsin, whereas about 30% of serum PSA occurs in a
noncomplexed free form. Several thousand reports on this
indisputable urological marker have already been pub-
lished, identifying PSA as the most useful biomarker for
detecting prostate cancer at an early stage, for evaluating
disease progression and for assessing therapeutic
response, as well as for identifying tumour recurrence [1].
Only recently several publications have shown that PSA is
expressed, at lower concentrations than in prostate or in
seminal fluid, in a variety of human tumour types, healthy
tissues, biological fluids and cell lines [4]. Here we sum-
marize the biomolecular findings and the conflicting
results on PSA expression in female breast tissues and
fluids (Table 1), focusing our attention on its potential use-
fulness for clinical applications in breast diseases.
PSA synthesis and secretion in normal and
diseased breast tissues
In 1989, PSA expression was first discovered [5] through
immunohistochemical reactions in some apocrine foci of
female fibrocystic breast tissue as well as in breast cancer
(BC), casting doubt on the specificity of this kallikrein only
for prostatic epithelium. Starting from 1994, Diamandis et
al [6] identified PSA immunoreactivity in at least 30% of
BC cytosolic extracts. Immunohistochemical studies
revealed that the intense PSA immunoreactivity identified
in BC was well correlated with that detected by
immunoassays [7]; western blotting and chromatographic
analyses demonstrated that breast tumour PSA had the
same molecular mass as seminal or prostatic PSA [6,8].
Molecular analysis revealed that the messenger RNA of
breast tumour PSA was identical in sequence to prostatic
PSA [9]; DNA sequencing confirmed that no mutations
were present in the coding region of the PSA gene in BC,
whereas frequent multiple mutations were revealed in
5¢-flanking regions [10].
Although the molecular and physiological mechanisms
behind PSA gene regulation by steroid hormones have not
yet been fully explained, the expression of PSA gene in
human female breast tissue is under the control of steroid
hormones, in particular androgens and progestins but not
oestrogens [11], through the activation of steroid-respon-
sive elements in the PSA promoter/enhancer region [12].
Not surprisingly, PSA positivity in breast tumours was not
univocally associated with oestrogen and progesterone
receptor positivity [13,14]: in fact, most PSA-producing
BCs are positive for steroid hormone receptor, but not all
tumours that are positive for steroid hormone receptor
produce PSA [15].
PSA production in healthy mammary tissue and in benign
breast disease tissues has also been debated; in fact,
several authors have demonstrated that PSA is expressed
at low levels in about 30% of normal breast tissues [16]
and that this production is under a specific hormonal
control (for example PSA production through the action of
progesterone and androgens but not oestrogens) [17].
Although the protein levels of PSA in female breast tissue
are generally quite low (analysed both by commercially
available enzyme immunoassays and by in-house immuno-
fluorometric immunoassay [4]), the highest expression of
PSA in breast tissue at both the protein and the mRNA
levels is seen in benign diseases, and the lowest expres-
sion is seen in advanced stage cancerous tissue, suggest-
ing that PSA expression in malignant breast tissues is
generally lower than in benign hyperplastic foci or healthy
tissue [16]. In contrast, recent evidence has reported a
lack of expression in normal breast tissues [18], casting
doubt on the breast tissue as the main source of PSA in
human females.
PSA as a potential prognostic factor
The fact that not all breast tumours and BC cell lines
produce PSA prompted studies on the use of PSA as a
prognostic indicator in BC. Some authors found that PSA
positivity in BC was significantly associated with smaller
tumours, progesterone and/or androgen receptor positivity
(and also with diploid tumours, early disease stage,
younger patient age and lower risk of relapse), describing
PSA as a valuable tool for the prediction of a ‘favourable’
BC prognosis and response to endocrine therapy [19,20].
Table 1
Main reports of biomolecular expression of prostate-specific
antigen related to the human female breast
Source References
Tissue from healthy breast [16–18]
Tissue with benign breast disease [5,16]
Tissue with breast cancer [6–8,13,14–16,21]
Association with steroid-hormone receptors [6,8,11,13–15,17]
Use as a prognostic indicator [7,14,16,20–23,45]
Gene and mRNA [9–12,15]
Breast cancer cell lines [11,24,25,34]
Milk [26,27]
Colostrum [28]
Breast cyst fluid [30,32–36]
Nipple aspirate fluid [27,31,38–40]
Serum of healthy and diseased females [16,19,20,22,35,41,43,44]Breast Cancer Research    Vol 3 No 4 Mannello and Gazzanelli
In contrast, other studies have suggested a lack of value of
PSA immunoreactivity in BC patients as a general prognos-
tic marker for BC [7,14]. Moreover, induction of serum
PSA is also associated with an ‘unfavourable’ prognosis in
BC patients with tumours that are positive for oestrogen
receptor [21,22] or in those receiving adjuvant treatment
[23], contradicting the reports of ‘favourable’ outcome in
patients bearing BC whose tumours showed PSA positivity
and who received no drug therapy [20], and apparently in
contrast with the induction of PSA synthesis observed in
vitro [11,24]. This controversy has no obvious explanation
at present and more studies are needed to understand the
function of PSA in BC and to identify PSA unequivocally as
a potential tool for the prediction of BC prognosis.
PSA production in vitro
Similarly to what has been shown in vivo, several BC cell
lines that are positive for steroid hormone receptor can be
induced (for example by mineralocorticoids, glucocorti-
coids, androgens and progestins but not by oestrogens)
to produce PSA [11,24], even if not all of these cell lines
can constitutively produce PSA [25]. The following BC
cell lines positive and negative for steroid hormone recep-
tor were used to evaluate the induction of PSA synthesis
and secretion: BT-20, BT-474, MCF-7, MDA-MB-231,
MDA-MB-435, MFM-223, T-47D and ZR-75-1 [11,24,25].
The lack of PSA expression in some receptor-positive BC
cell lines (as has also been observed in certain receptor-
positive breast tumours) might be due to different mecha-
nisms affecting the expression level of PSA (for example
either the absence or dysfunction of the necessary com-
ponents for PSA transcription/translation or a mutation/
polymorphism in the promoter/enhancer region of the
gene encoding PSA) [12]. However, the production of
PSA mediated by steroid hormones and their receptors
suggests that PSA might be a new marker for steroid
hormone action in female BC cells, even if the behaviour
of this proteolytic enzyme in vitro is not always correlated
with the results obtained in vivo (such as treatment with
tamoxifen) [20,21,23,24].
PSA expression in breast secretions
Milk and colostrum
PSA immunoreactivity in breast milk of normal lactating
women was first identified in 1995 [26]: PSA concentra-
tions were quite variable, were not correlated with the age
of the mother or the sex of the newborn, and tended to
decrease with increasing time after delivery, perhaps
because of the decrease in stimulating steroids after
removal of the placenta. PSA was found in milk predomi-
nantly in its free form (about 75%) [26,27], whereas in
colostrum around half of the molecules were complexed
with protease inhibitors [28]. Surprisingly, only few results
are available on the expression levels of PSA in milk during
lactogenesis [26], and none have yet been published on
the concentration of serum PSA during lactation, whereas
these biological aspects have been widely studied during
pregnancy [4,29]. Recent papers have demonstrated,
through an ultrastructural analysis of breast duct cells
found in milk and also in nipple aspirate fluids (NAFs) and
breast cyst fluids, that these apocrine cells are able to syn-
thesize and secrete PSA [27,30,31], suggesting that
these biosynthetically active cells might be the source of
PSA in milk and other breast extracellular fluids.
Although these results seem to suggest a possible synthe-
sis and secretion of PSA during lactation, the biological
function and physiological significance of different molec-
ular forms of PSA in milk are still unknown (for example, is
free PSA an enzymically active fraction involved in the
hydrolysis of milk proteins or is it able to act as growth
factor regulator?).
Breast cyst fluids
Starting from 1996 [32,33], it has been demonstrated that
most breast cyst fluids aspirated by needle from women
affected by gross cystic breast disease (GCBD) might
accumulate appreciable amounts of immunoreactive PSA
intracystically (up to 0.5 mg/l). Since then, over the course
of several studies, it has been shown that the intracystic
accumulation of PSA was associated more with metaboli-
cally active secretive/apocrine type I cysts than with tran-
sudative/flattened type II cysts and that the ratio of free
PSA to complexed PSA differs between the two cyst
types [34–36]. These findings suggest PSA as a further
biomarker for the subclassification of the GCBD, provid-
ing a new and valuable tool for the discrimination of gross
cysts at higher risk of subsequent BC [35,36]. Moreover,
it has been shown that intracystic carcinoma of the female
breast can produce and accumulate large amounts of
PSA in extracellular fluid from breast cyst fluid, probably
under the control of the progesterone receptors [8]. A
recent study demonstrated that the intracystic PSA accu-
mulated in breast cyst fluid is a secretory product of the
apocrine cells lining type I cysts [30], suggesting the
involvement of this serine protease in the mechanism of
GCBD formation and in its predisposition to preneoplastic
transformation [37].
NAFs
Several studies have demonstrated that NAFs contain
immunoreactive PSA at very high levels (up to 10 mg/l)
[27,38], suggesting PSA as a potentially useful biomarker
in risk assessment for BC. In fact, the concentrations of
PSA in NAFs were higher in premenopausal than in post-
menopausal women, in association with the higher levels
of circulating steroid hormones [39] (inversely associated
with risk for BC [40]); higher levels of PSA were found in
NAF from women with no risk factors for BC. Recently it
has been demonstrated that breast epithelial cells found in
NAF can synthesize and secrete PSA protein, suggesting
that the ductal lobular unit of the breast is a possiblesource of PSA that accumulates in very large amounts in
extracellular fluids of NAF [31].
Molecular forms of PSA in serum from
women affected by breast diseases
The recent use of ultrasensitive PSA immunoassays has
enabled the detection of PSA in at least 50% of normal
female serum [41], even if at concentrations of about 500
times lower than in male serum. This finding suggests as
possible sources both the mammary ductal system [16,30]
and the endometrium [29,42], two of the major hormonally
responsive tissues in females. Not surprisingly, an associa-
tion between serum PSA concentrations and circulating
steroid hormone levels has been demonstrated [43].
Although serum PSA levels are elevated in most
endocrine-dependent disorders [2,4], the presence of cir-
culating serum PSA in both healthy females and in
patients affected by breast diseases remains under
dispute. In fact, several studies suggested that some
benign breast diseases (for example GCBD and fibroade-
noma) and breast tumours might be the sources of higher
levels of PSA in serum [19,20,44] as the result of an
altered hormonal balance [2], triggering the aberrant
expression of hormone-dependent genes (such as PSA).
Of particular importance were the findings that the two
major molecular forms of PSA are differently accumulated
in the serum of the healthy and the diseased female
breast: in the vast majority of sera of healthy women and
patients affected by benign breast diseases, PSA seems
to be mostly complexed to a1-antichymotrypsin [20], and
in a significant proportion of females with BC the predomi-
nant serological isoform is the free form of PSA [44].
In contrast, recent studies have shown that the concentra-
tion of serum PSA in BC is not always directly correlated
with that in breast tumours and that PSA expression in
serum does not distinguish healthy women and/or women
with benign breast diseases from patients with BC
[7,14,18,22]. However, more evidence is needed to evalu-
ate whether free PSA might have potential clinical applica-
bility as a circulating marker for breast tumours, because
free PSA occurs at very low concentrations in serum, is
incapable of binding to proteinase inhibitors, and does not
always permit a distinction between healthy and benign
diseased patients [14,22]. Moreover, given that the gene
and mRNA for PSA are not modified in breast tumours, it
will be of greater importance to provide further information
on the nature of circulating free PSA in BC patients (for
example post-translationally modified PSA and/or free
PSA circulating as nicked/zymogenic protein).
Conclusions
Although potentially exciting, the proposed use of PSA as
a further biomarker for BC risk assessment must be
viewed with caution; it is needed to understand the possi-
ble ‘new’ physiopathological function(s) of this ‘old’
antigen; in fact, this kallikrein-like protease is thought to
participate in pathways that are involved in prostate
tumour initiation and/or progression, modulated through
its hormone dependence. A multitude of unanswered
questions exist regarding the functional role(s) of
extraprostatic PSA, in particular in human female breast
tissues. Multidisciplinary results add support to the notion
that PSA is a widespread kallikrein-like serine protease
and focus attention on the novel expression of PSA by
human breast tissue and fluids, in which PSA might act
both as a growth factor modulator and as a
translational/post-transcriptional protein regulator. In fact,
PSA has the following properties: it has no kininogenase
activity; it hydrolyses insulin chains, extracellular matrix
laminin and fibronectin, and interleukin-2; it enzymically
digests insulin-like growth factor binding proteins, and
probably also single-chain urokinase-type plasminogen
activator; it activates latent transforming growth factor; it
inactivates protein C inhibitors; it stimulates the conver-
sion of oestradiol to oestrone; it releases angiostatin-like
fragments by digestion of plasminogen; and it regulates
the hormonal bioactivity of parathyroid hormone-related
protein [42,45].
The proteolytic activity of PSA on these different biologi-
cal substrates, all detected in breast tissues and fluids,
could explain in part the novel potential functions of PSA
in female breast, not only as a sensitive molecular marker
implicated in responsiveness to hormone but also as an
initiator of the protease cascade, an important biological
mechanism for tissue remodelling in the breast [8,16].
Moreover, PSA might represent a potential good thera-
peutic target, but both overexpression and underexpres-
sion of the gene encoding PSA should be examined
because the enzymic activity of this serine protease could
be either beneficial or deleterious. In fact, it remains
uncertain whether mammary PSA is enzymically active
(and therefore could be involved in the promotion of
tumour growth and metastasis through the proteolytic
degradation of peculiar proteins) or inactive (expressed
as zymogenic, nicked or tumour-specific post-translation-
ally modified enzyme, and then capable of having a detri-
mental role in cancer progression or even of having a
functional role in the inhibition of tumour progression
through apoptotic pathways) [46].
As with physiological phenomena, novel discoveries on
PSA have obscured and complicated the understanding of
this kallikrein-like serine protease, giving rise to the notion
that PSA can no longer be regarded as a tissue-specific or
tumour-specific marker only for prostatic tissue but as a
ubiquitous molecule that can be synthesized and secreted
by cells bearing specific steroid hormone receptors under
conditions of steroidal modulation or stimulation. As always
happens with biomedical novelties, the potential for clinical
Available online http://breast-cancer-research.com/content/3/4/238
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marker in breast diseases is under debate: the molecular
forms of PSA are invaluable markers in human male prosta-
tic diseases, but much literature is accumulating at an
alarming rate on extraprostatic PSA, and in particular on
the new function(s) of PSA both as a prognostic tool for
BC risk assessment and a biomarker in the prediction of
response to the treatment of breast diseases [19]. Given
the dire need for tumour markers, only further studies can
establish the utility of PSA in the detection and treatment of
breast diseases and provide irrefutable evidence for its
diagnostic and/or prognostic use as a new weapon against
human breast cancer.
Nec scire fas est omnia [We are not permitted to
know everything]
Horace, Odes, Book IV, 4
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